IMR Press / FBL / Volume 20 / Issue 4 / DOI: 10.2741/4334

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Rational clinical trial design for antibody mediated renal allograft injury
Show Less
1 Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester NY, USA
2 Center for Biodefense Immune Modeling, University of Rochester Medical Center, Rochester NY, USA
Academic Editors:Ogo Egbuna, Jean Francis
Front. Biosci. (Landmark Ed) 2015, 20(4), 743–762;
Published: 1 January 2015

Antibody mediated renal allograft rejection is a significant cause of acute and chronic graft loss. Recent work has revealed that AMR is a complex processes, involving B and plasma cells, donor-specific antibodies, complement, vascular endothelial cells, NK cells, Fc receptors, cytokines and chemokines. These insights have led to the development of numerous new therapies, and adaptation of others originally developed for treatment of hemetologic malignancies, autoimmune and complement mediated conditions. Here we review emerging insights into the pathophysiology of AMR as well as current and emerging therapies for both acute and chronic AMR. Finally, we discuss rational clinical trial design in light of antibody and B cell immunobiology, as well as appropriate efficacy metrics to identify robust protocols and therapeutic agents.

Kidney Transplant
Antibody Mediated Rejection
B cells
Back to top